Monitoring rates of chlamydia re-testing within the English National Screening Programme, January 2013 to June 2016

Health Protection Report
Volume 11 Number 20
9 June 2017
Monitoring rates of chlamydia re-testing within the English National Screening Programme, January 2013 to June 2016

Key points

- Young adults who test positive for chlamydia are at high risk of repeat infection(s) [1-8].
- Since August 2013, the NCSP has recommended that young adults who test positive for chlamydia be routinely offered a re-test around three months after completing treatment.
- This analysis shows that, between January 2013 and June 2016, quarterly rates of re-testing 7-14 weeks after diagnosis peaked at 14% in Jan-Mar 2015 for non-specialist sexual health services (SHSs) and 13.8% in Jan-Mar 2016 for specialist SHSs.
- In non-specialist SHSs re-testing rates fluctuated but a decline was seen in the most recent data. Within specialist SHSs there was an upward trend in re-testing rates.

Background

The English National Chlamydia Screening Programme (NCSP) recommends that sexually active 15 to 24 year-olds are tested for chlamydia annually and on change of sexual partner. Young adults who test positive for chlamydia are at increased risk of subsequently testing positive compared to those who initially test negative [1-8]. Possible reasons for such repeat infections include non-compliance with treatment, incomplete or unsuccessful partner notification, unsafe sexual behaviours and treatment failure of the index patient or a partner [9].

In 2012-13 the NCSP carried out a consultation on whether individuals diagnosed with chlamydia should be routinely offered re-testing following a chlamydia diagnosis. The consultation found that both health professionals and young adults supported a recommendation for routine re-testing. Both groups emphasised that the offer of a re-test should be part of case management and should not replace the need for partner notification or advice on safer sex including condom use [10].

Following the consultation, the NCSP updated their recommendations for case management in August 2013, to include a routine offer of a re-test around three months after treatment completion [11]. This report accompanies the data tables on chlamydia re-testing rates by PHE.
Centre area (PHE-C) and upper tier local authority (UTLA) (available here by PHE-C and by UTLA for users of the HIV-STI web portal). These data tables are available on an annual basis to aid local monitoring and decision making. A re-testing audit tool is also available here. For information on the methodology and data limitations of these analyses please refer to appendix 1 and 2.

**National rates of re-testing**

Since 2013, quarterly re-testing rates for England ranged between 10.8% and 14.0% for non-specialist sexual health services (SHSs) and between 11.5% and 13.8% in specialist SHSs. The data show that re-testing rates within non-specialist SHSs fluctuated, and fell 14% from 12.6% to 10.8% in the first two quarters of 2016. Re-testing rates in specialist SHSs have increased by 11% from 11.7% in Q1 2013 to 13.0% in Q2 2016. Positivity at re-test was consistently higher in specialist SHSs (16.4% - 18.6%) than in non-specialist SHSs (11.2% – 13.4 %) (figure 1).

*Figure 1: Chlamydia re-testing rates within 7-14 weeks following a positive diagnosis and positivity at re-test by quarter, non-specialist and specialist SHSs, January 2013 – June 2016, 15-24 year-olds, England*
Local rates of re-testing

Rates of re-testing varied considerably by UTLA. Re-testing rates ranged from 0-29% (median 9.8% IQR: 7.2-13.0%) in non-specialist SHSs and from 5-32% in specialist SHSs (median 15.0% IQR: 11.8-19.0%) (figure 2). Positivity at re-test is not presented by UTLA as the numbers are too low in many for meaningful interpretation.

Figure 2: Chlamydia re-testing rates within 7-14 weeks following a positive diagnosis by UT local authority, April – June 2016, 15-24 year-olds, England*

* UTLAs excluded where < 10 diagnoses. UTLAs also excluded from non-specialist SHS analyses where >20% of records were missing required data items. Of the 152 UTLAs in England, 110 for non-specialist SHSs and 87 for specialist SHSs met the criteria for inclusion in the analysis above.
**Discussion**

This report provides an update for monitoring rates of chlamydia re-testing using the two national STI surveillance systems. Despite the limitations of these data (appendix 2), our findings suggest that in 2016, as few as one in seven chlamydia diagnoses among young adults were followed by a re-test within seven to 14 weeks.

Since the NCSP recommendation for offer of re-test was incorporated into case management guidance in August 2013 the surveillance data does not provide strong evidence of a change in re-testing rates at the national level in either non-specialist or specialist SHSs. However, we can only measure re-testing coverage; offer of re-test is not captured in surveillance datasets.

Re-testing rates by UTLA show large variation which may be attributable to small numbers of index diagnoses. Most UTLAs have re-testing rates below 20% in both non-specialist and specialist SHSs. PHE has produced a re-testing monitoring tool [13] to allow commissioners to explore their local re-testing figures in more detail. The national audit report on chlamydia re-testing is available here. In spring 2016 PHE launched a series of Chlamydia Care Pathway workshops with local area commissioners and providers to support local teams to improve the quality and efficiency of their chlamydia screening services. The importance of re-testing is highlighted in these workshops.

Positivity at re-test is higher than the positivity seen overall in both specialist and non-specialist SHSs: 13.0% vs. 7.7% in non-specialist SHSs and 18.0% vs 11.1% in 2016 in specialist SHSs [14]. The proportion of patients who re-tested positive in specialist SHSs was consistently higher than those re-tested in non-specialist SHSs. These findings support the inclusion of offer of re-test at around three months within the NCSP case management guidance.

There are several approaches that can be taken to incorporate re-testing into the patient care pathway and different methods that could be used to recall patients [15]. Local examples are discussed in the document “Chlamydia re-testing of positive cases: models of existing practice” [16] available here. The relative cost of implementing different methods of recall for re-testing is dependent upon existing local practices.

* Re-testing positivity figure based on January-June 2016 data and overall positivity based on January-December 2016 data.
References

Appendix 1: Data collection and methodology

Routine surveillance data on chlamydia testing from the Chlamydia Testing Activity Dataset (CTAD) and Genitourinary Medicine Clinic Activity Dataset (GUMCADv2), collected by Public Health England [12], were used for this analysis. Quarterly re-testing rates (defined as the proportion of individuals with a chlamydia diagnosis for whom another test was recorded within the subsequent 7-14 weeks) among 15 to 24 year-olds were calculated for each UTLA and PHE-C for January 2013 to June 2016. Positivity at re-test was calculated for England and PHE-C areas.

Re-testing rates in non-specialist SHSs, and in specialist SHSs, were calculated separately because it is not possible to track individuals moving between specialist and non-specialist SHSs. Non-specialist SHS data were derived from CTAD and a combination of data items was used to match individuals between different non-specialist SHSs. Specialist SHS data were derived from GUMCADv2 and clinic-specific identification numbers were used to link unique patient records. Thus, for specialist SHSs, re-testing rates can be calculated only within (and not between) services.

The England and PHE-C totals for non-specialist SHSs excluded data from UTLAs where >20% of records were missing the required combination of data items. Specialist and non-specialist SHS data presented by UTLA also excluded any UTLA with fewer than 10 diagnoses per quarter. The proportion of UTLAs whose data were included in the analysis has improved from 75% in quarter 1 (Jan-Mar) 2013 to 85% in quarter 4 (Oct-Dec) 2016.
Appendix 2: Data limitations

The data presented here underestimate true re-testing rates due to the following limitations in the data available from the CTAD and GUMCADv2 national surveillance systems:

• individuals cannot be matched across non-specialist and specialist SHSs in CTAD and GUMCADv2

• individuals cannot be matched between specialist SHSs in GUMCADv2 because numbers linking patient records are unique only within a clinic

• a proportion of non-specialist SHS records were reported without the data items required to monitor re-testing. Since monitoring began this figure has been reduced from 25% in Q1 2013 to 15% in Q2 2016 so we can be more confident in the accuracy of these re-testing estimates.

Accuracy and interpretation of monitoring re-testing rates using surveillance data could be improved by:

• increased completion of data items submitted to CTAD

• better understanding of the proportion of patients who are likely to retest in a different service from their initial test, either by moving between specialist SHSs, or between specialist and non-specialist SHSs. We recommend LAs check patient pathways to determine the extent to which this may affect their data.
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

About Health Protection Report

*Health Protection Report* is a national public health bulletin for England and Wales, published by Public Health England. It is PHE’s principal channel for the dissemination of laboratory data relating to pathogens and infections/communicable diseases of public health significance and of reports on outbreaks, incidents and ongoing investigations.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG
Tel: 020 7654 8000  www.gov.uk/phe
Twitter: @PHE_uk  Facebook: www.facebook.com/PublicHealthEngland
Queries relating to this document should be directed to:
HIV and STI Department,
National Infection Service, PHE Colindale,
61 Colindale Avenue, London NW9 5EQ.
gumcad@phe.gov.uk

© Crown copyright 2017
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published June 2017
PHE publications gateway number: 2017109